Kodiak Sciences Inc.
BAKER BROS. ADVISORS LP (Director) buys KOD shares
About this filing
Kodiak Sciences Inc. (KOD) filed Form 4 (insider transaction) with the SEC on Nov 6, 2026. Form 4 reports a company insider’s trades in the company’s shares.
Key facts
- Insider 1
- BAKER BROS. ADVISORS LP · Director
- Insider 2
- 667, L.P. · Director
- Insider 3
- Baker Bros. Advisors (GP) LLC · Director
- Insider 4
- Baker Brothers Life Sciences LP · Director
- Insider 5
- Felix Baker · Director
- Insider 6
- Julian Baker · Director
| Date | Transaction | Shares | Price | Value | Held after | Ownership |
|---|---|---|---|---|---|---|
| Nov 4, 2026 | P · purchaseFootnotes F1, F2, F3 | +8,742 | $98.51 | $861,174.42 | 1,678,469 | Indirect (See Footnotes) |
| Nov 4, 2026 | P · purchaseFootnotes F2, F3, F4 | +151,916 | $98.51 | $14,965,245.16 | 20,343,130 | Indirect (See Footnotes) |
| Nov 5, 2026 | P · purchaseFootnotes F1, F2, F3 | +4,703 | $98.51 | $463,292.53 | 1,683,172 | Indirect (See Footnotes) |
| Nov 5, 2026 | P · purchaseFootnotes F2, F3, F4 | +81,729 | $98.51 | $8,051,123.79 | 20,424,859 | Indirect (See Footnotes) |
Footnotes
- F1 After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Biotech Capital, L.P. and (ii) 667, L.P. ("667"), Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in the common stock ("Common Stock") of Kodiak Sciences Inc. (the "Issuer") reported in column 5 of Table I held directly by 667, a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP), LLC, due to their interest in 667 and Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667.
- F2 Baker Bros. Advisors LP (the "Adviser") serves as the investment adviser to 667 and Baker Brothers Life Sciences, L.P. ("Life Sciences", and together with 667, the "Funds"). In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds. Baker Bros. Advisors (GP) LLC (the "Adviser GP") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds.
- F3 Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose.
- F4 After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Brothers Life Sciences Capital, L.P. and (ii) Life Sciences, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in the Common Stock reported in column 5 of Table I held directly by Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to their interest in Life Sciences and Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences.
Remarks: Felix J. Baker, a managing member of Baker Bros. Advisors (GP) LLC, the sole general partner of Baker Bros. Advisors LP, is a director of Kodiak Sciences Inc. (the "Issuer"). By virtue of their representation on the board of directors of the Issuer, for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, the reporting persons other than Felix J. Baker are deemed directors by deputization of the Issuer.
More KOD filings
- 4
Filed Oct 26, 2026
- 4
Filed Oct 23, 2026
- 144
Filed Oct 21, 2026
- S-3ASR
Filed Oct 20, 2026
- SC 13D/A
Filed Sep 30, 2026
- 4
Filed Sep 30, 2026
Not investment advice. Summaries can contain errors; the SEC filing is the official record.